DXCM's Q1 earnings expectations for next year are not currently available. Here's a summary of the available data and analysis:
- Earnings and Revenue Forecasts: Currently, there are no available data or forecasts for DXCM's Q1 earnings and revenue next year. The latest available data is from Zacks Investment Research, which provides a consensus EPS forecast of $0.33 for the quarter1. However, this does not represent a full-year forecast.
- Recent Performance and Analyst Ratings:
- DXCM's stock has received a consensus rating of "buy" from analysts, with an average rating score based on 32 buy ratings, 18 hold ratings, and no sell ratings2.
- The median target price for DXCM's stock is $127.56, with a high estimate of $165.00 and a low estimate of $75.002. This suggests a potential upside from the current price, but does not provide specific Q1 earnings expectations.
- Government Coverage Expansion: DXCM has recently seen an expansion of public coverage for its continuous glucose monitoring systems in Saskatchewan, Canada. This could potentially lead to increased demand and revenue for the company3. However, this development does not directly impact Q1 earnings expectations for next year.
- Insider Trading Activity: In a recent SEC filing, a director at DXCM sold 352 shares of the company's stock. This transaction is not indicative of Q1 earnings expectations, but it does reflect the current market sentiment and potential doubts about the company's short-term performance4.
In conclusion, there are no available data or forecasts for DXCM's Q1 earnings and revenue next year. The available information primarily pertains to current performance, analyst ratings, and recent news about the company's stock and market position. For specific Q1 earnings expectations, it would be necessary to wait for the company's official financial projections or updates from analysts.
4/4/2025 03:33am
